Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cost-effectiveness
100%
Health Policy
100%
Policy Model
100%
Quality-adjusted Life Years
100%
Hypertension
71%
Diabetes
57%
Disease Progression
42%
Patients with Diabetes
42%
Cost-effectiveness Ratio
42%
Age 50
28%
Chronic Kidney Disease
28%
Cost of Illness
28%
Microsimulation Model
28%
Annual Screening
28%
Universal Screening
28%
Health Care Costs
14%
Health Systems
14%
Simulated Patient
14%
Angiotensin-converting Enzyme Inhibitor (ACEi)
14%
Physician Visits
14%
Usual Care
14%
Model Simulating
14%
Outcome Costs
14%
Full Model
14%
Incremental Cost-effectiveness Ratio
14%
Systems Perspective
14%
Long Interval
14%
Angiotensin Receptor Blockers
14%
Screening Interval
14%
Patients with Hypertension
14%
Cost-effectiveness Model
14%
Long Time Horizon
14%
Nursing and Health Professions
Health Care Policy
100%
Cost Effectiveness Analysis
100%
Quality Adjusted Life Year
100%
Disease Exacerbation
42%
Chronic Kidney Failure
28%
Health Care Cost
14%
Healthcare System
14%
Patient with Diabetes
14%
Dipeptidyl Carboxypeptidase Inhibitor
14%
Incremental Cost-Effectiveness Ratio
14%
Patient with Hypertension
14%
Pharmacology, Toxicology and Pharmaceutical Science
Disease Exacerbation
60%
Chronic Kidney Failure
40%
Dipeptidyl Carboxypeptidase Inhibitor
20%
Angiotensin Receptor Antagonist
20%
Medicine and Dentistry
Microalbuminuria
100%
Population Model
12%